Breaking News on Global Pharmaceutical Technology & Manufacturing

Flamel to raise $62m in share offering

06-Oct-2003

Related topics: Delivery technologies, Regulatory & Safety

France's Flamel Technologies has started a drive to raise funds in the USA via a placement of shares aimed at raising $62.1 million.

The company's star has been in the ascendancy of late, having signed a string of licensing collaborations with pharmaceutical partners for its drug delivery technologies, designed to improve the administration of both small molecule and peptide/protein drugs.

 

Flamel has earmarked the funds for R&D activities and to augment its portfolio of drug delivery technologies, as well as general corporate activities. The company is enjoying a hike in revenues from licensing agreements and recently signed a $165 million deal with Bristol-Myers Squibb for an oral version of insulin formerly partnered with Novo Nordisk.

 

Flamel is developing new versions of undisclosed GlaxoSmithKline and Servier drugs, as well as a new sachet formulation of GSK's Augmentin (amoxicillin/clavulanate) antibiotic, using its Micropump controlled release technology for oral delivery of small-molecule drugs.

 

Copyright - Unless otherwise stated all contents of this web site are © 2012 - William Reed Business Media SAS - All Rights Reserved - For permission to reproduce any contents of this web site, please email our Syndication department copyright@wrbm.com - Full details for the use of materials on this site can be found in the Terms & Conditions

© 2012 - William Reed Business Media SAS - All rights reserved.